Objectives : This study investigated the improvement effects of Gangjihwan-1,2,3,4 (DF-1,2,3,4) and combination of DF-1 and Gamisochehwan (GSH) on nonalcoholic fatty liver disease in a high fat diet-fed obese mouse model. Methods : Eight-week-old C57BL/6N mice were divided into eight groups: a normal lean group given a standard diet, an obese control group given a high fat diet, and atorvastatin, DF-1,2,3,4, and DF-1+GSH groups given a high fat diet with atorvastatin (10 mg/kg), DF-1,2,3,4 (40, 80, 160, 80 mg/kg), and DF-1+GSH (80 mg/kg), respectively. After 8 weeks of treatment, body weight gain, blood lipid markers, ALT concentrations, liver weight and histology were examined. Results : Body weight gain was significantly decreased in DF-1,2,3,,4, DF-1+GSH and atorvastatin groups compared with control. The extent of decreases was eminent in DF-1+GSH group. Circulating concentrations of total cholesterol and LDL-cholesterol were significantly decreased in DF-2, DF-4, DF-1+GSH and atorvastatin groups compared with control. Liver weights, hepatic lipid accumulation and hepatic fibrosis were significantly decreased in DF-1,2,3,4, DF-1+GSH and atorvastatin groups compared with control, and the magnitude of which was more effective in DF-1+GSH group than in DF-only group. Circulating ALT concentrations were significantly decreased only in DF-4 and DF-1+GSH groups. Conclusions : In conclusion, these results suggest that DF decreases body weight gain, improves blood lipid metabolism, and reduces liver weight and hepatic lipid accumulation and hepatic fibrosis, contributing to the improvement of nonalcoholic fatty liver disease. In addition, these effects were more effective in DF-1+GSH combination group than in DF-only group.